|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsor: | Illinois Retina Associates |
|---|---|
| Collaborator: |
Alcon Laboratories |
| Information provided by: | Illinois Retina Associates |
| ClinicalTrials.gov Identifier: | NCT00690313 |
Purpose
Antibiotic eye drops are being used before and after intravitreal injections. Currently there is no study indicating the benefit of there usage or their dosage.
In this study we compare the efficacy of Vigamox eye drops (antibiotic)starting 3 days prior to the injection versus 1 day prior to intravitreal injection.
| Condition | Intervention | Phase |
|---|---|---|
|
Intravitreal Injection Patients |
Drug: Vigamox |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | To Compare the Efficacy of Topical Vigamox Eye Drops at Tid 3 Days Prior to Intravitreal Injection Versus Tid 1 Day Prior to Intravitreal Injection |
| Estimated Enrollment: | 40 |
| Study Start Date: | July 2008 |
| Estimated Study Completion Date: | September 2009 |
| Estimated Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Arm 1
Arm 1: receives Vigamox eye drops 3Xday for 3 days prior to intravitreal injection
|
Drug: Vigamox
eye drops 3 times day either 1 or 3 days prior to intravitreal injection
|
|
Active Comparator: Arm 2
Arm 2: receives Vigamox eye drops 3Xday for 1 day prior to intravitreal injection
|
Drug: Vigamox
eye drops 3 times day either 1 or 3 days prior to intravitreal injection
|
Eligibility| Ages Eligible for Study: | 21 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Kourous A Rezaei, MD | 708-596-8710 | karezaei@yahoo.com |
| Contact: David J Baczewski | 708-915-6808 | davidb@illinoisretina.com |
| United States, Illinois | |
| Illinois Retina Associates | Not yet recruiting |
| Harvey, Illinois, United States, 60426 | |
| Contact: David J Baczewski 708-915-6808 davidb@illinoisretina.com | |
| Principal Investigator: Kourous A Rezaei, MD | |
| Principal Investigator: | Kourous A Rezaei, MD | Illinois Retina Associates SC |
More Information
| Responsible Party: | Kourous Rezaei MD, Illinois Retina Associates SC |
| ClinicalTrials.gov Identifier: | NCT00690313 History of Changes |
| Other Study ID Numbers: | Vig508 |
| Study First Received: | May 30, 2008 |
| Last Updated: | June 3, 2008 |
| Health Authority: | United States: Institutional Review Board |
|
Vigamox, topical antibiotics, Intravitreal injections, macular degeneration, endophthalmitis |
|
Tetrahydrozoline Moxifloxacin Norgestimate, ethinyl estradiol drug combination Nasal Decongestants Vasoconstrictor Agents Cardiovascular Agents Therapeutic Uses Pharmacologic Actions Respiratory System Agents Sympathomimetics |
Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Infective Agents Contraceptives, Oral, Combined Contraceptives, Oral Contraceptive Agents, Female Contraceptive Agents Reproductive Control Agents |
